UK Framework Distribution Agreement with Diagmed Healthcare

UK Clinical Education Program to be imitated alongside Market Seeding

Creo Medical Group plc (AIM: CREO) (“Creo” or the “Company”), a medical device company focused on the emerging field of surgical endoscopy, today announces that is has entered into a framework distribution agreement with Diagmed Healthcare Limited (“Diagmed”).

Under the terms of the agreement, Diagmed will collaborate with Creo over an 18-month period to seed the UK market with Creo’s CROMA advance energy platform and Speedboat products.  The agreement requires Diagmed to purchase a minimum quantity of CROMA advance energy platforms and Speedboat products from Creo during the first 18 months.  In line with Creo’s education led commercial strategy, Diagmed will also advance the roll out of Creo’s Clinical Education Programme in the UK, to ensure quality control and best patient outcomes through the education of key clinicians in the use of Speedboat and the CROMA platform.  Once the seeding phase is complete, it is intended that Diagmed and Creo will enter into a further agreement where Diagmed will be Creo’s sole distributor for Creo’s CROMA advanced energy electrosurgery platform and Creo’s suite of GI devices in the UK, making Diagmed Creo’s second distributor alongside Hoya Group, Pentax Medical.

Diagmed Healthcare is the UK’s leading, independently owned endoscopy and diagnostic equipment specialist with a customer base extending to 536 medical facilities in the UK. It has developed strong and long-term relationships with globally renowned KOLs in world class centres of excellence as part of its clinical training programme.  This will help support Creo’s future R&D product development pipeline and its commercialisation.  The UK represents a significant marketing opportunity for Creo, both within the NHS and private practitioners.

Creo’s CROMA’s electrosurgical platform combines bipolar radiofrequency for precise localised cutting and microwave energy for controlled coagulation.  Speedboat RS2 is the first product approved in a suite of tools under development to aid the endoscopist in minimally invasive surgery.  The Speedboat device helps reduce the risks associated with alternative open and laparoscopic procedures, reducing the length of hospital stays, cost of treatment and transferring therapy from the operating theatre to the endoscopy room.

Craig Gulliford, Creo’s Chief Executive Officer, commented:

This agreement is the next significant milestone in the commercialisation of our lead product, Speedboat RS2.  Creo is dedicated to improving patient outcomes and helping clinicians by bringing advanced energy to the emerging field of surgical endoscopy.  Speedboat is paving the way for our suite of GI devices under development which we believe are the next generation of minimally invasive surgery tools and transformational technology.  Our products are rapidly gaining traction in the endoscopic field and with Diagmed as our UK partner, their expertise and knowledge in this important market will prove invaluable to Creo as we build our reputation worldwide.

Posted 07/04/18

For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.

Further news

19 March 2024

Welsh Labour Leader visits Creo’s facilities

Read

05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi

Read

31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific

Read

10 January 2024

First Use of Speedboat® UltraSlim in Latin America

Read

13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch

Read

01 November 2023

Speedboat® UltraSlim: US FDA Clearance

Read

25 October 2023

Speedboat UltraSlim: EU launch accelerated by 18 months

Read

12 September 2023

Half Year Report: H1-2023

Read

19 June 2023

Speedboat Inject cleared for upper GI use in Europe

Read

01 June 2023

Speedboat™ Inject selected by NICE for assessment

Read